Defining the Ideal Tumor Marker for Prostate Cancer

Montie, James E.; Meyers, Stephanie

doi:10.1016/s0094-0143(05)70369-4

Cited by 21 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data are still not sufficient for recommendation of routine use of any of the breast or ovarian cancer markers 12. Prostate specific antigen and prostate specific membrane antigen, diagnosed with immunohistochemistry, have long since been used as serum tumour markers of relapse in prostate cancer15; they have sometimes even been used for population screening and diagnosis 16. Recently, the detection of circulating prostate cancer cells in the bloodstream by using a reversed transcriptase and polymerase chain reaction assay for prostate specific antigen has been investigated as a predictor of surgical failure, and further development and use of this technique could give clinically relevant information 17…”

Section: Tumour Markers In Malignant Diseasementioning

confidence: 99%

Regular review: Tumour markers in malignancies

Lindblom

Liljegren²

2000

BMJ

View full text Add to dashboard Cite

Section: Tumour Markers In Malignant Diseasementioning

confidence: 99%

Regular review: Tumour markers in malignancies

Lindblom

Liljegren²

2000

BMJ

View full text Add to dashboard Cite

“…The clinical utility of PSA as a marker for prostate cancer emerged in 1980 with the initial report of elevated PSA levels in the serum of prostate cancer patients [27]. Since this time, the use of PSA as a tumor marker has flourished and PSA has proven to be the most useful marker in urologic oncology [28]. PSA immunoassays are widely used to detect early stage prostate cancer, to evaluate disease progression, and to assess therapeutic response [29].…”

Section: Psa As An Oncologic Markermentioning

confidence: 99%

The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast

Black

Diamandis

2000

Breast Cancer Res Treat

View full text Add to dashboard Cite

Although prostate-specific antigen (PSA) is the most valuable tumor marker for the diagnosis and management of prostate carcinoma, it is widely accepted that PSA is not prostate specific. Numerous studies have shown that PSA is present in some female hormonally regulated tissues, principally the breast and its secretions. In this review, we summarize the findings of PSA in the breast, and focus on its potential for clinical applications in breast disease. PSA is produced by the majority of breast tumors and is a favorable indicator of prognosis in breast cancer. Low levels of PSA are released into the female circulation, and while the level of serum PSA is elevated in both benign and malignant breast disease, the molecular form of circulating PSA differs between women with and without breast cancer. These findings indicate that PSA may have potential diagnostic utility in breast cancer. PSA may also have a clinical application in benign breast disease, as both the level and molecular form of PSA differ between Type I and II breast cysts. High levels of PSA have been reported in nipple aspirate fluid (NAF) and recent studies have shown that the concentration of PSA in NAF is inversely related to breast cancer risk, indicating that NAF PSA may represent a clinical tool for breast cancer risk assessment. Thus, PSA represents a marker with numerous potential clinical applications as a diagnostic and/or prognostic tool in breast disease.

show abstract

“…In this study, the value of PSA was found decreased in serial estimation of PSA levels during one year follow up. Montie, et al and Stamey, et al [12,13] described 3 cases with 9 year follow up and reported importance of PSA in establishing the diagnosis of metastatic stage of prostatic cancer and also provided information on the course of the disease and response to treatment. Myrtle, et al [14], Staney, et al [15] and Gutha, et al [16] had reported a correlation between clinical stages and PSA levels.…”

Section: Discussionmentioning

confidence: 99%